[225Ac]Ac-AKY-1189
- Urothelial Cancer
- Breast Cancer
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Cervical Cancer
- Undisclosed indication
Aktis Oncology
Most recent annual filing: 2026-03-15
- AKY-2519 Ph1 startMid-2026AKY-2519 Ph1 start, Mid-2026, notable
- Aktis cGMP manufacturing facility update2H 2026Aktis cGMP manufacturing facility update, 2H 2026, routine
- cGMP facility manufacturing update2H 2026cGMP facility manufacturing update, 2H 2026, routine
- BActinium-2 Ph1 start2H 2026BActinium-2 Ph1 start, 2H 2026, routine
- CMO 10b5-1 plan filingSep 23, 2026CMO 10b5-1 plan filing, Sep 23, 2026, routine
- AKY-1189 Ph1 interim1Q 2027AKY-1189 Ph1 interim, 1Q 2027, major
- Two early pipeline programs corporate1Q 2027Two early pipeline programs corporate, 1Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (10 active programs)
[225Ac]Ac-AKY-2519
AKY-2519- Prostate Cancer
- Non-Small Cell Lung Cancer
- Undisclosed indication
- Small Cell Lung Cancer
Technology platforms
miniprotein radioconjugate platform · Eli Lilly
Proprietary miniprotein radioconjugate platform using polypeptides of 40-70 amino acids to selectively deliver alpha- or beta-emitting radioisotopes to solid tumors with high tumor penetration, prolonged retention, and rapid clearance from normal tissues. Leverages yeast surface display, AI/generative AI, and medicinal chemistry for discovery. Collaboration with Eli Lilly to generate novel anticancer radiopharmaceuticals against additional targets beyond the company's unpartnered pipeline.
miniprotein radioconjugate platform · Eli Lilly and Company
Proprietary, isotope-agnostic miniprotein radioconjugate platform designed to selectively deliver radioisotopes to targeted tumors; enables high tumor penetration, internalization and retention, and rapid clearance from normal tissues; supports imaging and therapeutic isotopes; focused on solid tumors including prostate, lung, urothelial, and breast cancers
Biotech Distilled coverage (4)
- 2026-08-14 UPDATE: Aktis Oncology (AKTS) - Boring Quarter, Interesting Footnotes 🔒 Paid
- 2026-05-21 UPDATE: Aktis Oncology (AKTS) - The Canary Sings 🔒 Paid
- 2026-05-12 UPDATE: Aktis Oncology (AKTS) - Fast Track, ASCO Date, and the Clock Starts on the Mid-2026 De-risker 🔒 Paid
- 2026-04-30 Aktis Oncology (AKTS) - Scientific Deep Dive for AKY1189 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.